Cetuximab plus irinotecan in refractory colorectal cancer patients

References

• Sato JD, Kawamoto T, Le AD et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med.1, 511–529 (1983).
   PubMedGoogle Scholar
• Kawamoto T, Sato JD, Le A et al. Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl Acad. Sci. USA80, 1337–1341 (1983).
   PubMed Web of Science ®Google Scholar
• Masui H, Kawamoto T, Sato JD et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res.44, 1002–1007 (1984).
   PubMed Web of Science ®Google Scholar
• Mayer A, Takimoto M. Fritz E et al. The prognosis significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer71(8), 2454–2460 (1993).
   PubMed Web of Science ®Google Scholar
• Hemming AW, Davis NL, Kluftinger A et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol.51(3), 147–152 (1992).
   PubMed Web of Science ®Google Scholar
• Vande Woude GF, Schutz N, Zhou R et al. Cell cycle regulation, oncogenes, and antineoplastics drugs. In: Accomplishments in Cancer Research Foundation. Fornter JG, Rhoads JE (Eds). JB Lippincott Co., PA, USA 128–143 (1990).
   Google Scholar
• Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colo-rectal cancer: a cohort study. Lancet Oncol.6(5), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Recker K. Specific EGFR inhibition with cetuximab, promising efficacy in combination and monotherapy and management of EGFR inhibitor-related skin reactions. In: Targeting Cancer. Springer, Heidelberg, Germany 2 (2004).
   Google Scholar
• Tsuruo T.Matsuzaki T, Matsushita T et al. Antitumor activity of CPT-11 a new derivative of camptothecine against pleiotropic drug-resistant tumors in vitro and in vivo. Chemother. Pharmacol.21, 71–74 (1988).
   PubMed Web of Science ®Google Scholar
• De Forni M, Bugat R, Chabot GG et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res.54, 4347–4354 (1994).
   PubMed Web of Science ®Google Scholar
• Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin.Oncol.15, 251–260 (1997).
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol.19(5), 1501–1518 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer92, 1331–1346 (2001).
   PubMed Web of Science ®Google Scholar
• Spano J.P, Fagard R, Soria J.C et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann. Oncol.16(2), 189–194 (2004).
   Google Scholar
• Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J. Clin. Oncol.20, 2217–2219 (2002).
   PubMed Web of Science ®Google Scholar
• Prewett MC, Hooper A, Bassi R et al. Enhanced antitumor activity of anti-epidermal facto receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Cancer Res.8(5), 994–1003 (2002).
   Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT11) is active in CPT11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol.22 (2002) (Abstract 7).
   Google Scholar
• Van Cutsem E, Mayer RJ, Gold P et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur. J. Cancer (Suppl. 2), 85–86 (2004) (Abstract 279).
   Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Saltz L, Kies M, Abbruzzese J et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 817).
   PubMed Web of Science ®Google Scholar
• ESMO minimum clinical recommendations. Ann. Oncol.16(Suppl. 1), I16–I17 (2005).
   PubMed Web of Science ®Google Scholar
• Chung KY, Kemeny NE, Shah M et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9), 1803–1818 (2005).
   PubMed Web of Science ®Google Scholar
• Hebbar M, Wacrenier A, Desauw C, et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs17(7), 855–857 (2006).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Lenz H, Hchster H et al. Cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 3508).
   Google Scholar
• Wilke H, Glynne-Jones R, Adenis A et al. MABEL – a large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 3549).
   PubMedGoogle Scholar
• Tejpar S, Peeters M, Humblet Y et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 3554).
   Google Scholar
• Van Cutsem E, Humblet Y, Gelderblom H et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment(EVEREST): preliminary PK and efficacy data of a randomized study. Ann. Oncol. (Suppl. 9), Iba 4 (2006).
   Google Scholar
• Lang I, Zaluski J, Changchien CR et al. Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (MCRC): preliminary safety results (Crystal). Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 3555).
   Google Scholar
• Díaz Rubio E, Tabernero J, van Cutsem J et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international Phase II study. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 3535).
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cervantes A, Martinelli E et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 308).
   PubMedGoogle Scholar